<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119473">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02078570</url>
  </required_header>
  <id_info>
    <org_study_id>dtectDx-Breast-002</org_study_id>
    <nct_id>NCT02078570</nct_id>
  </id_info>
  <brief_title>Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Provista Diagnostics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Provista Diagnostics, Inc</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The major purpose of this study is to evaluate a laboratory developed test that measures
      multiple breast cancer-specific biomarker proteins and multiple antibodies in your blood
      samples. The biomarker and antibody results along with your personal medical profile will be
      evaluated to determine your risk for the presence of a malignancy in the breast as compared
      to your breast evaluation assessment conducted by your physician.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Quantitative Protein Algorithmic Score (QPAS)</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Part I: Establish an acceptable algorithm for the generation of a single numerical score from the combination of the 10 cancer biomarkers that comprise the dtectDx Breast v2.0 Assay Part II: Define a numerical score cutoff that differentiates malignant from nonmalignant breast cancer in this population of woman</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Modified Quantitative Protein Algorithmic Score (QPAS)</measure>
    <time_frame>6 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Demonstrate proof-of-concept for use of the dtectDx-Breast Assay to assess likelihood of breast cancer malignancy in conjunction with the physicians clinical and radiological evaluations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QPAS relative to BI-RADS</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Demonstrate the numerical score, collaborated via proprietary algorithm , for the dtectDx-Breast Assay v2.0 increases the likelihood of malignant breast cancer detection when used adjunctively with the assessment of BI-RADS Categories 3 and 4 compared to the assessment of BI-RADS Categories 3 and 4 alone.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Breast Cancer ACR BI-RAD Category 3 or 4 result</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      35mL or 2 1/2 tablespoons of blood will be drawn from your arm
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Primary Care Clinics
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult women from 25 years of age to below 75 years of age

          -  Breast evaluation results of ACR BI-RADSÂ® Category 3 or 4 by imaging and physicians
             clinical and radiological evaluation

          -  Study visit and blood collection within 4 weeks (28 days)  of ACR BI-RADS assessment

          -  Patient agrees to with additional health data being gathered at 6 months post
             assessment for diagnostic follow-up

          -  Samples collected under IRB approval and Informed Consent

          -  Testing performed under IRB approval or waiver (as applicable)

          -  Previous approved procedures to enroll patients: breast augmentation &amp; cyst
             aspiration

        Exclusion Criteria:

          -  Adults from 76 years of age or older and below 25 years of age

          -  Final breast evaluation results other than a ACR BI-RADS Category 3 or 4

          -  Subjects that have had a breast biopsy performed during the 6 months prior to the
             study visit

          -  Samples not collected under IRB approval and Informed Consent

          -  Testing not performed under IRB approval or waiver (as applicable)

          -  Prior breast cancer diagnosis.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sherri Borman</last_name>
    <phone>480-344-9210</phone>
    <email>bormans@provistadx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Scripps</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Valencerina</last_name>
      <phone>858-652-5538</phone>
      <email>Valencerina.MariaAnna@scrippshealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Alain Perez</last_name>
      <phone>858-554-9379</phone>
      <email>Perez.Alain@scrippshealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Carrie Constantini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tiffany Pearce</last_name>
      <phone>313-916-1784</phone>
      <email>Tpearce1@hfh.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sheba Kurian</last_name>
      <phone>313-916-7277</phone>
      <email>Skurian2@hfhs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Haythem Ali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Biren Shah, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Avera Research Institute</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Demouth</last_name>
      <phone>605-322-3295</phone>
      <email>Heidi.Demouth@avera.org</email>
    </contact>
    <contact_backup>
      <last_name>Daniel Norfolk</last_name>
      <phone>605-322-3291</phone>
      <email>Daniel.Norfolk@avera.org</email>
    </contact_backup>
    <investigator>
      <last_name>Josie Alpers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amy Krie, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.provistadx.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 14, 2014</lastchanged_date>
  <firstreceived_date>February 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
